Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Coagulation Disorders » Purpura
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Hemorrhage » Purpura
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Signs and Symptoms » Skin Manifestations » Purpura
Description
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS). MeSH
Hierarchy View
Subtype Terms (5)
IgA Vasculitis
16 drugs (12 approved, 4 experimental)
Purpura, Thrombocytopenic
9 approved drugs
Phase 3 Indicated Drugs (7)
Phase 2 Indicated Drugs (17)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (23)
Organization Involved with Phase 3 Indications (90)
Allergy Associates of the Palm Beaches, North Palm Beach, FL
Allergy, Asthma & Immunology Assoc., Omaha, NE
Anhui College of Traditional Chinese Medicine
Assistance Publique - Hôpitaux de Paris
Asthma and Allergy Center, Papillion, NE
Capitol Comprehensive Cancer Care Clinic
Case Western Reserve University
Fundação de Amparo à Pesquisa do Estado de São Paulo
Gruppo Italiano Malattie EMatologiche dell'Adulto
Hamilton Health Sciences Corporation
National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Allergy/Immunology Associates, Dallas, TX
People's Liberation Army of China
Sunshine Lake Pharma Co., Ltd.
Organization Involved with Phase 2 Indications (57)
Chengdu University of Traditional Chinese Medicines
China Academy of Chinese Medical Sciences
Etablissement Français du Sang
Fondazione Progetto Ematologia
Henan University of Traditional Chinese Medicine
Hospital Universitario Dr. Jose E. Gonzalez
Humanity & Health Research Centre
Icahn School of Medicine at Mount Sinai
Katholieke Universiteit Leuven
National Cancer Institute (NCI)
National Center for Advancing Translational Science (NCATS)
National Cheng Kung University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health (NIH)
Prof. Dr. I. Chiricuta Institute of Oncology
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (7)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
